Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA) identifier:
NCT02032823 (


Study Contact Information:

About the Study

The OlympiA trial is the first major study to test the PARP inhibitor olaparib (Lynparza) for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers. OlympiA is a phase III clinical trial looking at the safety and effectiveness of olaparib for women with stage 2 or 3 breast cancer with a BRCA mutation after they have completed standard therapy.

The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium. 

This Study is Open To:

The study is no longer enrolling patients. 

This Study is Not Open To:

The study is no longer enrolling patients. 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.